Q3 2026 Aquestive Therapeutics, Inc. Earnings Conference Call - AQUESTIVE THERAPEUTICS INC

Financial Performance:

• Q3 2026 total revenue was $7.6 million, down from $12.8 million in Q3 2025, driven by quarterly fluctuations in Suboxone product orders.
• For the first nine months of 2026, total revenue increased 14% to $35.8 million (vs. $31.5 million), primarily due to a $5 million increase in Zebra-related royalty revenue.
• Manufacturer and supplier revenue was $6.7 million in Q3 2026; license and royalty revenue was $0.8 million.
• Net loss for Q3 2026 was $16.5 million ($0.13/share), compared to $15.4 million ($0.14/share) in Q3 2025; YTD net loss narrowed to $47.4 million ($0.38/share) from $51.9 million ($0.51/share) in 2025.
• Non-GAAP-adjusted EBITDA loss narrowed to $12.2 million in Q3 2026 and $19.2 million YTD 2026 (from $35.5 million YTD 2025).
• Cash and cash equivalents stood at $90.3 million at September 30, 2026; excluding the $10 million Eton upfront fee received in October, the company expects to end 2026 with >$70 million in cash.
• Full-year 2026 guidance remains intact: total revenue of $46–50 million and non-GAAP adjusted EBITDA loss of $30–35 million.

Guidance and Future Outlook:

• FDA goal date for Anifilm is March 16, 2027; the company maintains this timeline despite hoping for an earlier decision.
• Launch readiness for Anifilm in the U.S. is on track for Spring 2027, contingent on FDA approval.
• Canadian filing for Anifilm expected by end of 2026; European filing targeted for Q1 2027.
• 2027 outlook focuses on launching Anifilm, delivering Phase 2 data for QST-108 in atopic dermatitis, and advancing Adreniverse proof-of-concept studies.
• Potential future capital access includes $75 million under RTW and $20 million under Oaktree facilities upon Anifilm approval, contingent on terms.
• Management expects to see "green shoots" in 2027 regarding payer coverage (percentage of covered lives), physician uptake, and spending efficiency.

Business Segments and Product Lines:

• Anifilm (Epinephrine Sublingual Film): Core growth asset; currently under FDA review with a resubmitted NDA. Company is hiring district sales managers and building a sales force of ~75 representatives targeting ~8,000 key accounts (allergists, pediatricians, ENTs).
• LiberVant (Diazepam Buccal Film): Out-licensed to Eton Pharmaceuticals for U.S. commercialization in 2027. Transaction includes $10 million upfront payment, up to $47.5 million in milestones, and a mid-teens royalty. Equestive retains exclusive manufacturing and supply rights.
• Base Business (Suboxone & DEA): Manufacturer and supplier revenue remains steady; Suboxone revenue is up year-to-date despite long-term decline trends.
• Adreniverse Pipeline: Focus on epinephrine pro-drugs; QST-108 for atopic dermatitis is the near-term priority, with plans to expand to other indications in 2027.

Market and Competitive Landscape:

• U.S. epinephrine market expected to grow year-over-year in 2027; transition from autoinjectors to new technologies (like Anifilm) is the long-term trend.
• Competitive differentiation emphasizes "speed" (pharmacodynamics) and ease of use over existing autoinjectors.
• Management notes that autoinjectors maintain dominance due to legacy status rather than superior clinical data, creating an opening for Anifilm.
• PBM discussions are ongoing with the top four PBMs to secure formulary access; pre-approval information exchange (PIE) is being used to present clinical data to stakeholders.

Risks and Challenges:

• Regulatory risk: Final FDA decision timing is uncertain; the company does not control the review schedule.
• Commercialization risk: Success depends on payer adoption, formulary placement, and physician confidence in the new delivery mechanism.
• Market adoption risk: Convincing caregivers and patients to transition from established autoinjectors requires significant education and trust-building.
• Financial risk: While liquidity is strong, future funding relies partly on contingent milestones and debt facilities that trigger upon Anifilm approval.

Management Commentary and Tone:

• Tone is confident and execution-focused; management highlighted the successful completion of three key 2026 promises (resubmission, out-licensing, debt refinancing).
• Shifted messaging strategy from emphasizing PK (pharmacokinetics) to PD (pharmacodynamics), arguing that the speed of symptom cessation is the critical differentiator for patients.
• Emphasized disciplined capital allocation, tight cash management, and the strategic value of the Eton partnership for Libervant.

Analyst Questions and Answers:

• Commercial Strategy: Sherry Chaffee confirmed a focused launch with ~75 reps targeting 8,000–8,500 physicians, avoiding broad TV spend initially in favor of targeted digital and field force activities.
• FDA Review Scope: Melina Chaffee clarified that the FDA review will focus strictly on addressing the Complete Response Letter (CRL) items, not a full re-review from scratch.
• PD vs. PK: Dr. Matt Greenhut explained that while PK data is strong, the clinically relevant metric for anaphylaxis is the time to peak heart rate and blood pressure (PD), with Anifilm showing peaks in 5–8 minutes vs. 11+ minutes for comparators.
• Pricing/Access: Management declined to disclose specific pricing but confirmed the use of standard launch tools like copay cards and patient support hubs.
• Manufacturing: Melina noted that while routine clinical site inspections are possible, the company is prepared for a Potential Pre-Approval Inspection (PAI) of their U.S. facility.
• Early Adopters: Sherry identified allergists as the primary target, followed by pediatricians and ENTs, with targeting informed by historical epinephrine prescription volume (including NEFI data).

Other Key Points:

• The company received a $10 million upfront payment from Eton Pharmaceuticals in October 2026 for the Libervant license.
• The $10 million Eton payment was excluded from the Sept 30 cash balance but is included in the >$70 million year-end cash projection.
• The Eton partnership allows Equestive to remain an exclusive manufacturer, preserving a revenue stream from Libervant while focusing commercial resources on Anifilm.
• Management intends to present new pharmacodynamic data at the American College of Asthma, Allergy and Immunology (ACAAI) conference in Phoenix.